Together, AtherOMICS enables multimodal characterization of human atherosclerosis aiming for the discovery of athero-specific drug targets, molecular signatures of atheroprogression, and noninvasive biomarkers of plaque vulnerability.
Abstract
Omics technologies enable deep profiling of human atherosclerosis but have mostly been applied in small studies lacking integration with other data modalities. AtherOMICS is a biobanking project linking multiomic atherosclerotic plaque phenotyping with blood biobanking, in vivo imaging, and clinical data. Here, we present the study protocol and show pilot results that demonstrate technical feasibility. Since August 2022, 246 patients scheduled to undergo carotid or femoral endarterectomy at Ludwig-Maximilians-Universität Klinikum (Munich, Germany), have been enrolled (median age, 73 years; 32% female), with recruitment ongoing. Plaques undergo systematic histological characterization of lipid core, calcification, intraplaque hemorrhage, fibrous cap, macrophages, and smooth muscle cells. Single-nucleus RNA sequencing (n = 17) has confirmed macrophages as the dominant intraplaque cell type, whereas paired plaque and plasma affinity–based proteomics (n = 88) quantified 2841 shared proteins showing low plaque-plasma correlation (median ρ = 0.10). Cross-modality image integration [histology, ex vivo magnetic resonance imaging (MRI), in vivo MRI, and computed tomography angiography] proved feasible. Together, AtherOMICS enables multimodal characterization of human atherosclerosis aiming for the discovery of athero-specific drug targets, molecular signatures of atheroprogression, and noninvasive biomarkers of plaque vulnerability.
Deep proteomic profiling of human carotid plaques identifies molecular signatures of symptomatic atherosclerosis that extend beyond conventional histopathology, which implicate neutrophil activation and inflammatory signaling pathways as key determinants of plaque vulnerability.
L. Zhang, L. Živković, A. Ray et al.· medRxiv· 0 citations
Findings identify GPR146 as a candidate molecule associated with plaque progression and instability, although its causal role requires further validation.
Qing Liu, Yu Geng, Yi-Fei Wang et al.· Frontiers in Cardiovascular...· 0 citations
Cardiovascular diseases (CVDs) represent a significant global health challenge. Low-intensity pulsed ultrasound (LIPUS), a non-invasive therapeutic approach, has emerged as a promising modality for promoting tissue repair, reducing inflammation, and improving microcirculation. This study employs a combination of biblio...
Xingyu Wang, Shiqi Wang, Yuantai Yu et al.· Ultrasound in Medicine and B...· 0 citations
The feasibility of region-resolved proteomics in individual murine aortas is demonstrated and new molecular insights into the site-specific nature of atherosclerotic plaque development are provided.
Kathrine V. Jokumsen, C. Christoffersen, M. Davies et al.· bioRxiv· 0 citations
Carotid plaque (CP) is a surrogate marker of cardiovascular disease, and high-risk morphology significantly increases the risk of stroke. The aim of this study was to develop advanced machine learning (ML) models to predict the presence of CP in the general population. The study involved 693 participants from the Polis...
A. Szpakowicz, W. Lesiński, J. Tuchliński et al.· PLoS ONE· 0 citations
Findings support ProAL50 as a biologically informative, protein-based surrogate of AL for research use that complements traditional AL, pending further external validation and assay standardization.
Yu-Fan Guan, Jie Shen, Li Li et al.· Proteomes· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.